Cell injection therapy for systemic sclerosis
Part of Skin clinical trials.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a confirmed diagnosis of systemic sclerosis (diffuse type) for 5 years or less.
- You should have a skin hardening score between 10 and 30 (measured by a doctor).
- You must have tried at least two previous treatments for your condition, like steroids or immune-suppressing drugs.
- You cannot have severe lung problems, recent heart issues, or certain other serious health conditions.
- You must not have had stem cell treatment before or be pregnant or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests an investigational cell therapy for people with systemic sclerosis (scleroderma). The treatment uses your own modified immune cells to try to calm the overactive immune system and slow the disease, with imaging to see where the cells go in your body.
This study tests an experimental cell therapy that targets your own immune cells to treat systemic sclerosis (scleroderma) with lung involvement. It aims to see if this treatment works better than standard care in reducing disease activity.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
This trial tests a new treatment using your own immune cells, modified to attack faulty cells that drive systemic sclerosis. It's for people with active disease who haven't improved with standard therapies.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.